PPIDT00252
Drug Information
| Name | Vedolizumab |
|---|---|
| Sequence | QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB09033 |
| Type | biotech |
| Indication | Vedolizumab is indicated for adult patients with moderately to severely active Ulcerative Colitis or Crohn’s disease.[L48216, L51763] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Intravenous |
300 MG/5ML
|
| Injection, powder, for solution | Intravenous |
30000000 mg
|
| Injection, powder, for solution | Intravenous |
33100000 mg
|
| Injection, powder, for solution | Intravenous; Parenteral |
300 MG
|
| Injection, powder, lyophilized, for solution | Intravenous |
300 mg/5mL
|
| Injection, solution | Subcutaneous |
108 MG
|
| Powder, for solution | Intravenous |
300 mg / vial
|
| Solution | Intravenous |
300.000 mg
|
| Solution | Subcutaneous |
108 mg / 0.68 mL
|
| Powder | Intravenous |
300 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
|
| Injection, solution | Subcutaneous |
108 mg/0.68mL
|
| Injection, powder, for solution | Intravenous |
300 mg
|
| Solution | Subcutaneous |
108.00 mg
|
| Solution | Subcutaneous |
10800000 mg
|
| Injection, solution, concentrate | Intravenous |
300 mg/1vial
|